Autonomix Medical's New Patent for Cancer Treatment
Autonomix Medical, Inc. has recently achieved a significant milestone by securing a U.S. patent that will enhance its innovative approach to treating cancerous tumors and relieving cancer-related pain. This new patent adds to Autonomix's growing global portfolio, which now boasts over 120 patents, including 80 that have been issued and more than 40 pending applications.
Insights into the Patented Technology
The newly issued U.S. patent, numbered 12,064,256, is titled 'Systems and Methods for Treating Cancer and/or Augmenting Organ Function.' This patent focuses on cutting-edge technology that encompasses a variety of methods, systems, and devices aimed at treating cancerous growths and alleviating associated discomfort. The company’s preliminary efforts will particularly target patients suffering from pancreatic cancer-related pain.
CEO's Perspective on the Patent's Importance
Brad Hauser, CEO of Autonomix, expressed the importance of augmenting their patent portfolio, saying, "As we continue to advance the development of this potentially groundbreaking technology, bolstering our patent protection remains a key priority." He highlighted the encouraging results from their recently completed preclinical study, which indicated a substantial reduction in both tumor mass and metastasis. The findings underscore the notable influence neural pathways have in the progression of pancreatic cancer.
Preclinical Study Findings
A recently conducted preclinical study involving mouse subjects was pivotal in demonstrating the efficacy of targeted nerve ablation. The results indicated a statistically significant decrease in metastases and tumor size, reinforcing the hypothesis that manipulating neural pathways can have an impactful role in combating pancreatic cancer. While the company is currently focused on a proof-of-concept human clinical trial for pain reduction through nerve ablation, they remain optimistic about exploring the clinical potential of their technology to decelerate cancer growth and spread.
Innovative Technology for Enhanced Treatment
Autonomix's first-in-class technology combines catheter-based sensing with advanced microchip capabilities. This innovative approach offers a remarkable ability to detect and differentiate neural signals, achieving approximately 3,000 times greater sensitivity than existing technologies. After identifying the target nerves, Autonomix employs proprietary radio frequency (RF) ablation techniques to deactivate these nerves, setting the stage for a targeted and precise management of various diseases ranging from chronic pain to cardiovascular issues.
Looking Ahead: The Potential of Autonomix Technology
With its global patent portfolio expanding, including the recently granted patents 12,053,634 and 12,070,334, Autonomix is well-positioned to pioneer new treatments in the medical field. The first patent, titled 'Endoscopic Sympathectomy Systems and Methods,' and the second, 'Elongated Conductors and Methods of Making and Using the Same,' further solidify their role as innovators in medical device technology.
About Autonomix Medical, Inc.
Autonomix Medical is dedicated to revolutionizing the diagnosis and treatment of conditions affecting the nervous system. Their technology platform holds promise not only for treating pain but also addresses various conditions across an extensive spectrum such as cardiology and hypertension. Despite the investigational status of their technology, the company is optimistic about its future implications.
Contact Information for Inquiries
For more information or inquiries, individuals can reach out to JTC Team, LLC. Jenene Thomas is available at 908.824.0775 for any questions regarding the company and its advancements. Autonomix encourages inquiries to further illuminate its technology's capabilities and potential.
Frequently Asked Questions
What is Autonomix Medical's new patent about?
The new patent focuses on systems and methods for treating cancerous tumors and related pain, particularly targeting pancreatic cancer.
How does the new technology work?
It utilizes catheter-based sensing and proprietary radio frequency ablation to detect and treat pain by targeting specific nerves.
What recent studies support Autonomix's technology?
A preclinical mouse study showcased a significant reduction in tumor mass and metastasis, supporting the effectiveness of their methods.
What are the future plans for this technology?
Autonomix aims to continue developing its technology with a focus on clinical trials and further investigations into its efficacy in treating cancer.
How many patents does Autonomix have now?
The company now has over 120 patents, comprising 80 issued and more than 40 pending applications.
